GbS Global Biopharma
GBS Global Biopharma, Inc. is a Canadian phytomedicine research and biopharmaceutical drug development company specializing in patented, plant-inspired therapeutic mixtures for prescription medications. Utilizing their proprietary PhAROS Drug Discovery Platform, which integrates AI technology and high throughput screening, they design minimum essential mixtures to preserve plant medicine efficacy while standardizing formulations. Their pipeline includes late preclinical programs with a lead candidate for Parkinson's disease advancing toward clinical trials. The company also develops therapies for pain, COVID-19 related cytokine release syndrome, and heart disease, supported by multiple issued US and international patents. Collaborations with top universities and industry partners enhance their R&D and drug delivery technologies, including oral nanoparticles and rapid dissolve formulations. GBS Global Biopharma aims to bring safe, effective, standardized cannabinoid medicines to market with rigorous scientific evidence and regulatory approvals.
GbS Global Biopharma
GBS Global Biopharma, Inc. is a Canadian phytomedicine research and biopharmaceutical drug development company specializing in patented, plant-inspired therapeutic mixtures for prescription medications. Utilizing their proprietary PhAROS Drug Discovery Platform, which integrates AI technology and high throughput screening, they design minimum essential mixtures to preserve plant medicine efficacy while standardizing formulations. Their pipeline includes late preclinical programs with a lead candidate for Parkinson's disease advancing toward clinical trials. The company also develops therapies for pain, COVID-19 related cytokine release syndrome, and heart disease, supported by multiple issued US and international patents. Collaborations with top universities and industry partners enhance their R&D and drug delivery technologies, including oral nanoparticles and rapid dissolve formulations. GBS Global Biopharma aims to bring safe, effective, standardized cannabinoid medicines to market with rigorous scientific evidence and regulatory approvals.